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Abstract
Summary If all adults with osteoporosis in the European Union (EU) and United States (US) used calcium and vitamin D
supplements, it could prevent more than 500,000 fractures/year in the EU and more than 300,000/year in the US and save
approximately €5.7 billion and US $3.3 billion annually.
Purpose Evaluate the cost-effectiveness of calcium/vitamin D supplementation for preventing osteoporotic fractures.
Methods A cost-benefit analysis tool was used to estimate the net cost savings from reduced fracture-related hospital expenses if
adults with osteoporosis in the EU and US used calcium/vitamin D supplements. A 14% relative risk reduction of fracture with
calcium/vitamin D supplementation from a recent systematic review and meta-analysis of randomized, controlled trials was used
as the basis for the benefit estimate. Other model inputs were informed by epidemiologic, clinical, and cost data (2016–2017)
obtained via the medical literature or public databases. Analyses estimated the total number of avoided fractures and associated
cost savings with supplement use. Net cost benefit was calculated by subtracting the supplements’ market costs from those
savings.
Results The > 30 million persons in the EU and nearly 11 million in US with osteoporosis experience about 3.9 million and 2.3
million fractures/year and have annual hospital costs exceeding €50 billion and $28 billion. If all persons with osteoporosis used
calcium and vitamin D supplements, there would be an estimated 544,687 fewer fractures/year in the EU and 323,566 fewer in
the US, saving over €6.9 billion and $3.9 billion; the net cost benefit would be €5,710,277,330 and $3,312,236,252, respectively.
Conclusions Calcium and vitamin D supplements are highly cost-effective, and expanded use could considerably reduce frac-
tures and related costs. Although these analyses included individuals aged ≥ 50 years, the observed effects are likely driven by
benefits observed in those aged ≥ 65 years.
Keywords Osteoporosis . Bone fracture . Calcium . Vitamin D . Costs and cost analysis . Cost savings
Introduction
According to the International Osteoporosis Foundation, os-
teoporosis is a worldwide epidemic [1]. Osteoporotic fractures
are often the first sign of the disease [2], and frequently occur
after a low-impact injury or fall, but vertebral fractures can
also occur during routine activities in the absence of a fall or
injury [2, 3]. Fractures result in pain, deformity, height loss,
impaired quality of life, restricted mobility, loss of indepen-
dence, and, especially in the case of hip fractures, increased
mortality [2, 3].
Recommended strategies for fracture prevention include,
among other things, adequate consumption of calcium and
vitamin D [2, 3]. Mineralization of bone requires calcium,
and dietary calcium absorption in the gut requires the presence
of vitamin D [4]. Vitamin D also supports bone growth and
remodeling by osteoblasts and osteoclasts [4]. For persons
aged 51 years and older, United States (US) dietary guidelines
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recommend a daily calcium intake of 1200mg for women and
1000 mg for men and a daily vitamin D intake of 600 mg for
both genders [5]. However, most North American osteoporo-
sis guidelines recommend a vitamin D intake of at least 800 to
1000 IU/day (maximum4000 IU/day) for adults aged 50 years
and older [2, 3, 6, 7]. European guidelines vary by country, but
a daily intake of at least 1000 mg of calcium, which includes
dietary sources of calcium, and 400 to 800 IU of vitamin D is
generally recommended [8, 9].
Unfortunately, calcium and especially vitamin D are both
underconsumed dietary nutrients [5], and inadequacies in
these nutrients are a key preventable risk factor for osteopo-
rosis [10]. Among persons who rely on food alone for their
vitamin and mineral intake, about 38% consume inadequate
levels of calcium and about 93% consume inadequate levels
of vitamin D [11]. Vitamin D is also produced in the skin in
response to sunlight, but sunshine exposure may be limited by
climate or sunscreen use [5]. About 58% of persons in Europe
have serum 25-hydroxyvitamin D levels < 30 ng/mL [12].
It remains controversial as to whether increasing dietary cal-
cium intake results in clinically meaningful fracture reduction
[13–15]. Also, calcium supplementation alone does not reduce
fracture risk compared with placebo [16]. However, calcium and
vitamin D supplementation is associatedwith a 14% reduction in
overall risk of fractures and a 39% reduction in risk of hip frac-
tures in generally healthy adults, according to a recent meta-
analysis [4]. Most professional guidelines from North America
and the European Union (EU) support the use of supplements to
maintain adequate calcium and vitamin D intake [2, 3, 6, 7, 9].
Expanded use of combined calcium and vitamin D supple-
ments has the potential to lower the risk of fracture. The fi-
nancial impact of such prevention efforts is unclear, however,
since the supplements have an associated cost and would need
to be used by a large number of people to prevent one fracture.
This analysis evaluated the net cost savings that could be
derived from reduced hospital expenses for bone fracture if
all adults aged 50 and older with osteoporosis in the EU and
the US used calcium and vitamin D supplements, assuming a
14% reduction of total fracture risk [4]. We hypothesized that,
despite the costs of the supplements, savings would be derived
from a reduction in fractures.
Methods
Target populations
This analysis calculated fracture risk reduction and cost sav-
ings from calcium and vitamin D supplements in target pop-
ulations consisting of adults aged 50 and older with osteopo-
rosis in the EU and US. In addition, analyses were performed
to evaluate risk reduction and cost savings in subgroups of
those populations by age (50–59 years, 60–69 years, 70–
79 years, and > 80 years) and gender. All analyses were per-
formed by Frost & Sullivan (San Antonio, TX, USA).
Identification of fracture risk and related costs
We derived overall EU and US population data, as well as
population data for individual countries and states, from
Eurostat [17], the US Census Bureau [18], and the Kaiser
Family Foundation [19]; data were adjusted to align with the
10-year age bands of the target populations and were also
sorted by gender. We modeled the current prevalence of oste-
oporosis by applying osteoporosis prevalence data from
Hernlund et al. [8] for the EU and Wright et al. [20] for the
US to current total population figures. Gaps in information,
including missing EU countries, were approximated using
similar findings from the nearest and most similar country
with complete information.
We modeled the number of osteoporosis-attributed frac-
tures using reported annual fracture incidence rates derived
from Kanis et al. [21] and Johnell et al. [22] for the EU and
Burge et al. [23] for the US. Our estimates are conservative in
nature because the data from Kanis et al. [21] are for hip
fractures only. As US state-level fracture rates were not avail-
able, we first applied the osteoporosis prevalence rates by state
from Wright et al. [20] to distribute expected osteoporosis-
attributed bone fractures. Relative incidence rates of
osteoporosis-attributed fractures for each EU country and
US state were then applied to current population data to obtain
estimated current osteoporosis-attributed bone fracture rates.
Future survey research is required to verify the latest osteopo-
rosis fracture rates. The incidence of fracture (F) in each target
population was then calculated as the number of fractures per
year/number of people with osteoporosis.
We modeled the estimated per-person and total annual
costs of an osteoporosis-attributed bone fracture using report-
ed costs fromHernlund et al. [8] for the EU andWeycker et al.
[24] and Burge et al. [23] for the US. Since the study by Kanis
et al. reported costs for base year 2010, we scaled these figures
upward to account for inflation, assuming a 2% annual growth
in per-fracture cost from 2010 to 2016. Purchasing power
parity (PPP) per EU country and US state was used to further
control and adjust for relative healthcare costs between coun-
tries and states. We relied on the data from Burge et al. [23] to
segment costs by gender, age, and US state and adjusted for
target population growth. We calculated the cost equivalent
for each of the estimated 2.3 million total fractures in 2016
bymultiplying the average cost of fracture (US $12,197) times
the PPP of each US state and a cumulative inflation rate of
43.7% between 2005 and 2016 (consistent with a conservative
estimate of about 3.6% annual growth of the US healthcare
spending [25]). Future survey research is required to verify the
estimated annual cost of an osteoporosis-attributed bone
fracture.
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Determination of expected impact of calcium/vitamin
D supplements on fracture risk
A search of the medical literature identified a recent, compre-
hensive meta-analysis of 7 randomized, controlled trials
[26–32] of calcium (500–1200 mg/day) plus vitamin D (400–
800 IU/day) supplementation for fracture prevention in gener-
ally healthy community-dwelling and institutionalized adults
conducted by the National Osteoporosis Foundation (Table 1)
[4]. The final analysis, published in a correction, reported a
summary relative risk estimate of 0.86 (95% CI, 0.75–0.98),
indicating that supplementation would reduce the overall pop-
ulation risk of osteoporotic fracture by 14% [4]. Thus, the cur-
rent analysis utilized a relative risk reduction (RRR) for total
fracture of 0.14 with calcium and vitamin D supplementation.
The RRR (0.14) was used to calculate the absolute risk
reduction realizable for each target population by multiplying
it by the target population’s incidence of an osteoporosis-
attributed bone fracture (F). Number needed to treat
(NNT)—i.e., the total number of people who would have to
be treated with the supplements to achieve one avoided frac-
ture event—was calculated as 1/(F – [F · RRR]).The number
of avoided fractures (N*) was calculated as the number of
people in the target population with osteoporosis multiplied
by the absolute risk reduction or the inverse of NNT.
Calculation of net realizable healthcare cost savings
A previously published cost-benefit analysis tool developed by
researchers at Frost & Sullivan was used for this analysis [33].
The following equation was used to calculate total potential sav-
ings (S) from reduced hospital services following osteoporosis-
attributed fracture that would be realizable if the entire target
population used a calcium and vitamin D supplement: S = h ·
N∗ where h is the expected per-person cost of an osteoporosis-
attributed bone fracture for a member of the target population
(Pop) derived as described above.
It is also necessary to take into account the cost of the calcium
and vitamin D supplement. Therefore, the net cost benefits (B)
that could be realized from avoided osteoporosis-attributed bone
fractures were calculated as B = S −C = S − (Pop · d ), where
cost savings S is calculated as described above and the total
population cost (C) of calcium and vitamin D supplementation
is represented by C=Pop · d where Pop is the total number of
at-risk people in the target population and d is the expected
annual per-person cost for a 1000-mg/day calcium and 600-IU/
day vitamin D supplement regimen. In order to have a reason-
able estimate of savings, we based supplement costs on calcium
and vitaminD doses at the relatively higher end of the usual dose
ranges studied in the meta-analysis on which the RRR was
based; these regimen levels represent mid to high doses of sup-
plements typically available to consumers from the marketplace.
A vitamin D dose of 600 IU (15 μg) per day has also been
established by the European Food Safety Authority as adequate
intake for adults to achieve a target serum 25-hydroxyvitamin D
concentration of 50 nmol/L [34]. Supplement cost (d), which
represents the average cost across a wide range of available
supplements, was determined based on market analysis per-
formed by Frost & Sullivan (unpublished data, 2017).
Note that the entire target population must take the given
regimen in order for the total number of avoided events to be
realized. Thus, B represents the net monetary benefits that use
of calcium and vitamin D supplements can yield through hos-
pital cost reduction with 100% utilization of supplements by
the target population.
Results
Osteoporosis, fractures, and associated hospital costs
In the EU, an estimated 30,485,309 persons aged 50 years and
older have osteoporosis, representing nearly 15% of persons in
that age range (Table 2). In the US, an estimated 10,887,910
persons aged 50 years and older have osteoporosis, representing
about 10% of the US population of that age (Table 2). Women
account for about 80% of those with osteoporosis in both the EU
and the US. Osteoporosis rates increase with age in both regions
and are about 7%, 12%, and 24% among persons in their 50s,
60s, and 70s in the EU and 5%, 8%, and 16% in those age
groups in the US, respectively. In both regions, a little more than
a quarter of those aged over 80 years have osteoporosis.
The estimated annual fracture incidence among persons
with osteoporosis is 12.9% in the EU and 21.4% in the US,
which translates to about 3.9 million fractures per year in
Europe and 2.3 million per year in the US (Table 2), respec-
tively. Although men have a lower risk of osteoporosis, those
with osteoporosis have a higher risk of fracture compared with
women with osteoporosis: 21.7%/year vs 10.6%/year in the
EU and 31.9% vs 18.9% in the US. Among persons with
osteoporosis, fracture rates appear to be similar across age
groups, at about 12–13% in the EU and 21–22% in the US.
In the EU, osteoporosis-related fractures result in hospital
costs of about €12,772 per person and over €50 billion annually
(Table 2), with women accounting for 66% of cases. Hospital
costs for osteoporosis-related fractures in the US are about
$12,197 per person and over $28 billion annually (Table 2),
with women accounting for about 71% of costs. Those aged
≥ 80 years account for about 26% of the total osteoporotic
fracture–related hospital costs in the EU and 29% in the US.
Fracture reduction with calcium and vitamin D
supplementation
Fifty-six people in Europe, or 34 people in theUS,would need to
be treated with calcium and vitamin D supplements to prevent
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one fracture in each of those target populations. Absolute risk
reduction would be 1.8% in Europe and 3.0% in the US. If
everyone aged 50 years and older took calcium and vitamin D
supplements, an estimated 544,687 fractures would be prevented
annually in the EU (Fig. 1a) and 323,566 would be prevented
annually in the US (Fig. 1b). The number of avoided fractures
would be higher in women than in men and would be highest
among those in their 70s in the EU and in those ≥ 80 years old in
the US compared with the other age groups (Fig. 1a and b).
Cost savings with calcium and vitamin D
supplementation
The reduction in fractures with calcium and vitamin D sup-
plementation would save nearly €7 billion in the EU and near-
ly $4 billion in the US annually (Table 3). Factoring in the cost
of the supplements, this would result in a net cost benefit of
approximately €5.7 billion (Fig. 2a) and $3.3 billion (Fig. 2b)
per year, respectively. The EU would save €5.58 in hospital
costs for each €1 spent on calcium and vitamin D supple-
ments, and the US would save $6.22 per $1 spent (Table 3).
Breakdowns of the net cost/savings ratio by EU country and
US state are provided in the Electronic Supplemental
Materials (Online Resource 1), which also contain a break-
down of the overall cost analysis by EU country
(Online Resource 2) and US state (Online Resource 3).
Additionally, data describing osteoporosis-attributed fractures
and related hospital expenditures in adults aged ≥ 50 years in
the EU by age and gender are included in Online Resource 4;
these data were not available for the US.
Fracture reductions in women would account for over €3.6
billion (~ 64%) of the cost savings in the EU (Fig. 3a) and
nearly $2.3 billion (~ 69%) of the cost savings in the US (Fig.
3b). Cost savings associated with calcium and vitamin D
supplementation increase with age in both populations up to
age 80 and then begin to plateau or decline due to
diminishing population levels for those in the age ≥ 80 cohort
(Fig. 3a and b).
a
b
Fig. 1 Estimated number of
fractures avoided annually, by
gender and age, with 100% use of
calcium and vitamin D
supplementation by adults aged
≥ 50 years in a the European
Union and b the United States
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Discussion
Dietary supplements are a simple, noninvasive measure with
potential preventive health benefits. The current analysis
supports our hypothesis and suggests that expanding the use
of these supplements to 100% of adults aged ≥ 50 years could
reduce the annual number of fractures by 544,687 in the EU
and 323,566 in the US, resulting in a net cost benefit of over
a
b
Fig. 2 Cost analysis: net
healthcare cost savings in terms of
reduced hospital costs for
osteoporosis-attributable fracture
if all persons aged ≥ 50 years used
calcium and vitamin D
supplements in a the European
Union and b the United States,
2016–2017
Table 3 Calcium and vitamin D
supplementation cost benefit
analysis, 2016–2017
European Union, € United States, US $
Cost savings (avoided hospital costs for osteoporosis-attributable fractures)
Total annual savings (S) 6,956,520,691 3,946,589,993
Per-person annual savings 228.19 362.47
Costs of calcium and vitamin D supplements
Total annual cost (C) per target population 1,246,243,361 634,353,741
Daily per-person cost 0.11 0.16
Annual per-person cost 40.88 58.44
Net cost benefits
Annual net cost benefit (S – C) 5,710,277,330 3,312,236,252
Net benefit/cost ratio (S/C) 5.58 6.22
Arch Osteoporos           (2019) 14:50 Page 7 of 12    50 
€5.71 billion and $3.31 billion, respectively, in avoided
fracture-related hospital costs. Thus, it can be concluded that
calcium and vitamin D supplements are highly cost-effective.
However, it is important to note that the benefits observed in
the overall population may in part be driven by greater reduc-
tions in the older populations, in particular in those aged
≥ 65 years, who comprise the majority of the population used
to calculate the risk reduction, have higher risks for
osteoporosis-related fractures, and may be more detrimentally
affected by vitamin D deficiencies. As noted above, the ben-
efits increased with age in these analyses. These findings may
assist persons with osteoporosis, their healthcare providers,
government and private insurance companies, and employers
in making decisions or recommendations that could help min-
imize current and future fracture risks and related costs.
Fracture reduction and cost savings were predicted for both
genders and across all age groups 50 years and older; however,
increased use of calcium and vitamin D supplementation by
women, particularly older women, has the potential to produce
the greatest benefits with regard to fracture reduction and cost
savings. One caveat is that our analysis applied a 14% reduction
in fracture risk with supplementation across all age groups and
both genders. The 14% total fracture reduction was derived from
the recent meta-analysis by Weaver and colleagues [4]; most of
the individuals enrolled in the studies included in that meta-
analysis were 65 years of age and older, and only 1 study con-
tributed data fromwomen aged 50 years and older (Table 1) [29].
Therefore, future cost-benefit analyses in this area may benefit
from additional analyses that control for age and determine the
benefits for the different age groups evaluated. Also, the studies
included in the Weaver et al. meta-analysis included fewer men,
and the authors did not attempt to determinewhether RRR varies
by age or gender. Although men have a lower baseline risk of
fracture [35], there is evidence in other studies andmeta-analyses
that they derive a benefit from calcium and vitamin D supple-
mentation similar to women [31, 36]. Further studies are needed
to confirm whether persons in their 50s derive the same benefits
from calcium and vitaminD supplementation in terms of fracture
reduction as older persons; it is possible that by applying the
sameRRR across all age groups, we have overestimated benefits
in this younger age group and also underestimated benefits in the
oldest groups. In addition, it should be noted that the original
meta-analysis evaluated fracture reduction with calcium and vi-
tamin D supplements in generally healthy adults, whereas our
cost analysis is limited to persons with osteoporosis, who repre-
sent a high-risk subgroup.
a
b
Fig. 3 Net cost benefits, by
gender and age, with 100% use of
calcium and vitamin D
supplementation by adults aged
≥ 50 years in a the European
Union and b the United States
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A previous cost analysis predicted that costs of
osteoporosis-related fracture in the US would grow from
$16.9 billion in 2005 to $25.3 billion in 2025 [23].
Similarly, another previous cost analysis estimated that overall
costs of osteoporotic fracture in Europe would increase from
approximately €37.4 billion in 2010 to nearly €46.8 billion by
2025 [8]. Using their initial costs as a base and adjusting for
price inflation and PPP between US states and EU countries,
we estimated that hospital costs related to osteoporotic frac-
tures have already exceeded $28.4 billion in 2016–2017 in the
US and €50.1 billion in Europe. Future survey research is
required to verify the estimated annual cost of an
osteoporosis-attributed bone fracture. Another analysis pre-
dicted that adequate dairy intake containing 1000 to
1500 mg/day calcium could provide a 20% reduction in frac-
ture risk and cost savings totaling $3.5 billion per year [37];
however, a subsequent meta-analysis found no overall associ-
ation between dairy consumption and hip fracture risk [15].
It should be noted that the 14% RRR may be a conserva-
tive estimate of fracture reduction with calcium and vitamin
D supplements. An earlier meta-analysis found vitamin D
supplements at doses of 482–770 IU/day with or without
calcium supplements were associated with a 20% reduction
in all nonvertebral fractures and an 18% reduction in hip
fracture [36]. In addition, the meta-analysis we used to derive
the RRR included studies of supplements containing 500–
1200 mg/day of calcium and 400–800 IU/day of vitamin D
[4]. On the other hand, we may have overestimated a benefit
of calcium in combination with vitamin D given the most
recent meta-analysis by Zhao and colleagues [38], in which
the authors found only a 10% nonsignificant reduction in
total fracture risk with these supplements (risk ratio = 0.90;
95% CI, 0.78–1.04). However, 1 of the 8 trials included in
that meta-analysis had a follow-up of less than 12 months,
which is too short for fracture benefits to be expected; half of
the studies had no control intervention; and the focus was on
individuals aged ≥ 50 years, which may have lessened the
impact that may have been observed in an older population.
These limitations may have prevented the authors from
documenting a benefit. Further, the most recent meta-
analyses by Bolland and colleagues, which concluded there
was no benefit of vitamin D on fracture risk, excluded all
trials of vitamin D plus calcium [39, 40].
Our analysis was based on costs of supplements containing
1000 mg/day calcium and 600 IU/day vitamin D. Additional
analyses to determine the exact impact of calcium and vitamin
D supplement dose on the relative risk of fracture and related
costs should be considered for future investigation, especially
since benefits of vitamin D supplementation have been found
to be dose related [36].
There are a number of challenges inherent to studies of
nutritional interventions. For example, control groups are not
truly untreated since they still have some level of intake from
diet, as well as production of vitamin D from sun exposure,
and possible intake of other dietary supplements containing
these nutrients. The underlying meta-analysis by Weaver and
colleagues [4] and the current cost analysis were not adjusted
for baseline dietary or supplemental calcium and vitamin D
intake. Data from the National Health and Nutrition
Examination Survey (NHANES) show that usual intake
among US adults age 19 years and older is 1061 ± 15 mg
calcium from food alone versus 1277 ± 1 mg from food and
supplements among supplement users; usual vitamin D intake
is 5.17 ± 0.16 μg from food alone versus 17.1 ± 0.3 μg from
food and supplements [11]. It can be seen from these
NHANES data that supplements often help bring calcium
and vitamin D intake closer to recommended levels.
Thereby, we note that the assumption of the current model
that each target population shifts from zero to 100% usage of
calcium and vitamin D supplements may overestimate the
expected cost-benefit, as we do not take into account that each
target population already includes some proportion of persons
who are regular users of calcium and vitamin D supplements.
Such individuals have therefore already realized the potential
risk- and cost-reducing benefits of these supplements. A 2017
survey of 2001 US adults (age 18 years and older) by the
Council for Responsible Nutrition found that 20% were using
calcium supplements and 28% were using vitamin D supple-
ments [41]. Thus, as a rough estimate, assuming that the 20%
of calcium supplement users were all also vitamin D supple-
ment users and that a similar proportion of the subgroup of
persons aged 50 years and older were regular users, then a
conservative estimate would be that at least 80% of persons
in this age group have not yet realized the benefits of regular
use. This still amounts to an unrealized potential reduction of
258,852 fractures and $2,649,789,001 net cost benefit in the
US. Future investigations should include sensitivity analyses
using different estimates of risk reduction and taking into ac-
count the impact of adherence and personal supplement use on
both fracture risk reduction and supplement cost.
This cost model is based on 100% adherence, which rep-
resents an ideal scenario not typical of real-world use.
Nonetheless, this model provides information as to maximum
potential benefit from calcium and vitamin D supplements in
the target populations, with the understanding that actual net
benefits would be lower with lower rates of supplement up-
take or less than 100% adherence among supplement users.
Currently, there is some controversy as to whether meta-
analyses of calcium and vitamin D supplements should in-
clude all subjects (intent-to-treat population) or only those
who were adherent during clinical trials [4, 29, 42]. Data from
the Women’s Health Initiative (WHI) studies have been ana-
lyzed using multiple approaches: an intent-to-treat approach
that evaluated the total population irrespective of adherence, a
subgroup analysis that included only those subjects who were
not taking personal supplements at baseline, and a per-
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protocol analysis that included only subjects who were not
using supplements at baseline and who then adhered to the
assigned supplement [29]. Not surprisingly, since treatments
can only work if they are taken, the third approach provided
the most compelling support for fracture reduction with calci-
um and vitamin D supplementation [29]. The meta-analysis
used to determine RRR for the current cost analysis included
the latter of these three groups from the WHI, and sensitivity
analyses conducted using the other WHI analysis populations
produced fairly similar results [4]. Data on fracture reduction
in the subgroup of adherent participants were lacking in other
studies included in the meta-analysis; however, it should be
noted that the 14% reduction in fracture was seen even with
less than 100% adherence in all of the trials [4]. In fact, re-
ported adherence rates were as low as 55% to 63% in some of
the included trials [28, 31]. Thus, the RRR used in this anal-
ysis is likely a conservative estimate of the benefit of supple-
ments, given that those in the placebo group still have some
baseline exposure to calcium and vitamin D and those in the
treated group were not fully adherent.
The RRR for fracture in this analysis was derived from a
meta-analysis in healthy community-dwelling and institution-
alized adults and applied to a subgroup of such persons with
osteoporosis; actual RRR may be higher or lower in this
subgroup. In addition, since a majority of fragility fractures
occur in persons with bone mineral density in the osteopenic
range [43], additional cost analyses are needed to identify
potential cost savings if calcium and vitamin D supplementa-
tion was expanded to include those with osteopenia, especial-
ly at elevated risk based on Fracture Risk Assessment Tool
thresholds (e.g., ≥ 20% 10-year probability for major osteo-
porotic fracture or ≥ 3% 10-year probability of hip fracture in
the US) [44].
The current analysis measures total benefits and does not
necessarily predict fracture risk and savings for individual
persons whose potential benefits vary with their specific risk
of osteoporosis-related fracture. Individual fracture risk is de-
pendent on a variety of factors such as age, race, gender, body
mass index, bone mineral density, previous fracture history,
health conditions (e.g., rheumatoid arthritis, hyperthyroidism,
chronic liver disease), concurrent medications (e.g., glucocor-
ticoids), and alcohol and tobacco use [44]. Evaluating the
effects of calcium and vitamin D supplements on fracture risk
would benefit from also evaluating their effects on bone qual-
ity. In addition, cost benefits might differ if looked at from
either a patient or a payer perspective instead of a societal
perspective. In real-world settings, actual costs are borne by
a combination of insurers and patients. While insurers proba-
bly cover a majority of the hospital-based costs associated
with fracture, patients likely bear the out-of-pocket costs of
over-the-counter supplements, although in Europe, individual
countries (e.g., Switzerland and Germany) reimburse the costs
via health insurance claims for patients with established
osteoporosis. Theoretically, if the out-of-pocket costs of the
supplements were shifted to insurers, the removal of a cost
barrier for patients could potentially lead to increased supple-
ment use and associated decreases in fractures that would still
result in cost savings for insurers based on the current analysis.
Only direct costs of hospitalization related to fracture were
included in this cost-benefit analysis. Thus, the analysis does
not take into account impact on other medical expenses (e.g.,
long-term care) or indirect costs (e.g., absenteeism and loss of
productivity) related to fracture, nor does it take into account
the impact to society of potential lost tax revenue. Some of
those costs can be extensive (e.g., the cost of long-term care
for disability from osteoporosis was €10.7 billion in Europe in
2010 [1]). Therefore, additional cost benefits beyond those
measured in this analysis are potentially realized if fractures
are reduced through expanded supplementation use.
As global populations continue to age, a considerable in-
crease in osteoporosis prevalence is anticipated [1]. In fact, the
number of individuals over the age of 50 years worldwide
who are at high risk of osteoporotic fracture is expected to rise
by about 30% in Europe andmore than 50% in North America
from 2010 to 2040 [45]. The current analysis suggests that
expanding combined use of calcium and vitamin supplements
among adults in this age group has the potential to reduce the
risk of fractures and substantially reduce hospital costs for
osteoporosis-attributable fractures. Potential cost savings
based on 2016–2017 data amount to over €5.71 billion and
nearly $3.31 billion per year in Europe and the US,
respectively.
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